About Mentor Capital

Mentor Capital targets warrant proceeds for operating cancer companies often like those in the Cancer Immunotherapy Index and to invest in those or related firms via stock purchase or acquisition. The company's advantage is to seek in depth medical science judgment to screen cancer breakthroughs for probable success well in advance of the FDA process. In the Mentor program, an identified cancer company enters into a Long-term Equity Funding Agreement with the company. The company receives cancer related shares that are held in escrow until the associated investment payable is retired. The cancer fighting company receives cash from warrant proceeds at an agreed upon fixed price. The mutually related funding contracts speed up payment to the cancer companies growing most quickly.